| WO2013096709 |
Moderna, USA |
Increasing the viability
or longevity of an organ or organ
explant using modified mRNAs for proteins essential for organ survival |
| WO2015058069 |
Moderna, USA |
Polynucleotides for tolerizing cellular
systems |
| WO2016201377 |
Moderna, USA |
Preparation of targeted
adaptive vaccines for treatment of
inflammatory disease, autoimmune disease and cancers |
| WO2017214175 |
Moderna,
USA |
Modified RNA encoding VEGF-A in formulations for
treatment
of heart failure and other diseases |
| WO2018160540 |
Sanofi, France; BioNTech,
Germany |
Therapeutic RNA and uses in treating solid tumor
cancers |
| WO2018222890 |
Arcturus Therapeutics, USA |
Synthesis
and structure of high potency RNA therapeutics |
| WO2019178006 |
SQZ Biotechnologies
Co., USA |
Immunogenic epitope and adjuvant-modified T
cells for intracellular
delivery of tumor or exogenous antigen to enhance immune response
against cancer and infection |
| WO2020056147 |
Moderna, USA |
Polynucleotides encoding glucose-6-phosphatase for the treatment
of glycogen storage disease |
| WO2020097409 |
Moderna, USA |
Use of mRNA encoding OX40L in combination with immune checkpoint
inhibitor to treat cancer in human patients |
| WO202011811 |
Arcturus
Therapeutics, USA |
Compositions and methods for treating
ornithine transcarbamylase
deficiency |
| WO2020154189 |
Sanofi, France |
Therapeutic RNA for treatment
of advanced stage solid tumor |
| WO2020227615 |
Moderna, USA |
Polynucleotides encoding methylmalonyl-CoA mutase for the treatment
of methylmalonic acidemia |
| WO2020260685 |
eTheRNA Immunotherapies,
Belgium |
Antitumor therapy comprising mRNA molecules
encoding tumor-associated
antigens and checkpoint inhibitors |
| WO2021021988 |
Translate Bio, USA |
Treatment of cystic fibrosis by delivery of nebulized mRNA
encoding Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) |
| WO2021058472 |
BioNTech and TRON, Germany |
Combination treatment
using therapeutic antibody and interleukin
2 (IL-2) |
| WO2021198157 |
BioNTech, Germany |
mRNA compositions (RiboMab) expressing claudin-18.2-targeting
antibody and anticancer uses thereof |
| WO202120771 |
Verve Therapeutics, USA |
Base editing of ANGPTL3 and methods of using same for treatment
of cardiovascular disease |
| WO2021214204 |
BioNTech, Germany |
RNA constructs and uses thereof |
| WO2022136266 |
BioNTech, Germany |
Therapeutic RNA for treating cancer |
